Laurus Labs share price today: key moves in 2026

Latest share price snapshots reported

Multiple price snapshots are cited across different market updates for Laurus Labs Ltd (NSE: LAURUSLABS). One update lists the share price on 14 May 2026 at ₹1,295.30. Another “share price update” mentions the stock moving up 3.94% from a previous close of ₹953.95, with a last traded price of ₹991.50.

A separate market snapshot pegs the share price at ₹837.75 with Open: ₹839.10, High: ₹846, Low: ₹825.05, Previous Close: ₹836.50, 52-week high: ₹846, and 52-week low: ₹414. These figures reflect how different time-stamped updates can show very different prices and ranges.

Recent returns and stated risk indicators

The dataset reports short-term returns of 9.23% (1 week), 18.54% (1 month), and 26.71% (3 months). It also flags the stock as “Moderate Risk” and notes it is 2.26x as volatile as Nifty.

On market size, one snapshot places Laurus Labs at a market cap of ₹69,128 crore with a rank of 155. Another update during a steep fall mentions the market cap dropping to ₹28,907.03 crore on the BSE, indicating these values refer to different points in time.

FY2026 business context: CDMO pivot highlighted

One business note says Laurus Labs recorded 23% revenue growth in FY2026, driven by an expanding CDMO business and a shift towards higher-value segments. The company is also described as targeting CDMO revenues to form 50% of total sales by 2030.

Separately, media reports cited in the dataset say the company’s export revenue declined 47% to about $16 million in February, pointing to a slowdown in overseas sales during that period.

Dividend yield and payout consistency

The data states Laurus Labs has shown an inconsistent dividend trend over the last five years. The current dividend yield is reported at 0.09%.

An illustration in the dataset adds that an investment of ₹1,000 is expected to generate a dividend of ₹0.94 per year, aligning with the low yield mentioned.

January 2026: record highs followed by a sharp pullback

A day-by-day summary for early January 2026 shows a surge to fresh highs, followed by profit-taking amid broader market weakness.

• Jan 6: New 52-week high at ₹1,129.25.
• Jan 7: All-time high at ₹1,131.20.
• Jan 8: Sharp decline on heavy volume.
• Jan 9: Week closed at ₹1,082.30 (weekly change -2.29%).

The same week summary also notes a week high of ₹1,134.20 and relative performance of +0.33% vs Sensex.

Q2 FY26 results: profit and margins jump

The dataset provides detailed numbers for the September 2025 quarter (Q2 FY26). Laurus Labs reported consolidated net profit of ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25. Revenue from operations rose 35.1% to ₹1,653.47 crore.

Segment and operating metrics in the data include:

• CDMO revenue: ₹518 crore, up from ₹339 crore a year earlier (stated as 53% growth).
• EBITDA: cited as ₹429 crore (vs ₹182 crore) with 26% margin in one update.
• Another update reports EBITDA of ₹403.3 crore (vs ₹178.3 crore) and 24.4% margin.

These multiple EBITDA figures appear across different reports within the dataset, but both indicate a sharp year-on-year improvement.

Analyst ratings and target prices: mixed calls

Brokerage views in the dataset span bullish to cautious. Motilal Oswal is cited as expecting a 50% earnings CAGR over FY25-28, reiterating a ‘Buy’ with a target price of ₹1,110. Choice Broking maintains a ‘Buy’ with a target of ₹1,085, referring to a shift toward a CDMO-led model and citing a PEG ratio of 0.94.

On the cautious side, Goldman Sachs is mentioned reiterating a ‘Sell’ and revising target price to ₹775 (from ₹750). Elsewhere, Goldman Sachs is also referenced with a ₹475 target in a separate note. Jefferies is cited maintaining ‘Underperform’ with a target of ₹480. Another note references a brokerage continuing with a ‘Hold’ and revising target to ₹810 (from ₹700), and Antique is cited with a ‘Hold’ and ₹520 target (previously ₹398).

The dataset also includes an S&P Global Market Intelligence summary stating 46.15% of analysts recommend ‘Hold’, with an average target price of ₹591.92, described as -29.34% versus a cited current price of ₹837.75.

Key numbers at a glance

Timeline table: early January 2026 move

Market impact and what investors tracked

The price action described in the dataset shows two recurring drivers. First, earnings-led optimism, especially around the Q2 FY26 jump in profit and improved margins, supported sharp rallies and new highs in parts of the period. Second, the stock also saw sharp declines tied to profit-taking and broader market weakness, including sessions where the Sensex fell materially.

There are also business-specific sensitivities highlighted, such as reported export weakness and references to antiretroviral (ARV) exposure in some analyst notes. The dataset includes a note that foreign-aid related headlines could affect ARV-linked sales, while another excerpt attributes a company clarification that ARV exposure to the US is limited, reflecting why investors may see conflicting narratives in the same period.

Conclusion

Laurus Labs’ FY26 coverage in the provided data combines strong quarterly execution and a stated CDMO-led strategy with noticeable share-price volatility and mixed analyst targets. Near-term attention in the dataset remains on earnings follow-through, segment traction in CDMO and formulations, and how export and ARV-linked factors evolve in subsequent updates.